Disease · MONDO_0009691

mycosis fungoides

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mycosis fungoides. Diseases, record MONDO_0009691. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009691

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mycosis fungoides; Open Targets
Open Targets ID: MONDO_0009691; Open Targets
Other names: CTCL/ mycosis fungoides, MF, cutaneous T-cell lymphoma/mycosis fungoides, mycosis fungoides (morphologic abnormality), mycosis fungoides NOS (morphologic abnormality), mycosis fungoides lymphoma, mycosis fungoides of unspecified site, mycosis fungoides, Alibert-Bazin type, mycosis fungoides, unspecified site, extranodal and solid organ sites; Open Targets
Disease Ontology: DOID:8691; Disease Ontology
MeSH: D009182; MeSH
NCI Thesaurus: C3246; NCI Thesaurus
Orphanet: ORPHA:2584; Orphanet
Highest stage of its drugs: Approval, for 7 of its 75 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs75

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MOGAMULIZUMAB	CHEMBL1743041	Antibody	Approval	DailyMed, EMA Human Drugs, FDA and TTD	16	12	12	Drugs and targets
MECHLORETHAMINE	CHEMBL427	Small molecule	Approval	EMA Human Drugs	8	7	7	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Approval	DailyMed	5	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
RESMINOSTAT	CHEMBL4296717	Small molecule	Preapproval	EMA Human Drugs	2	1	1	Drugs and targets
BRENTUXIMAB VEDOTIN	CHEMBL1742994	Antibody drug conjugate	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
VORINOSTAT	CHEMBL98	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 75

See all 75 drugs

Targets100

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
HDAC1	Histone deacetylase	3	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	3	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	3	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	3	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/10013	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	3	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
DHFR	Dihydrofolate reductase	2	Dihydrofolate reductase inhibitor	Approval	https://conductscience.org/library/genes/1719	Drugs and targets
HDAC10	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/79885	Drugs and targets

1 to 10 of 100

See all 100 targets

Trials89

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01728805	Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL	Phase 3	372	2019-04-11	Cutaneous T-Cell Lymphoma	MOGAMULIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02296164	Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma		300	2019-12-05	Mycosis Fungoides	MECHLORETHAMINE	Its record names the disease	ClinicalTrials.gov
NCT00168064	Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides	Phase 2	260	2012-10-31	Mycosis Fungoides	MECHLORETHAMINE	Its record names the disease	ClinicalTrials.gov
NCT00425555	Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma	Phase 2	139	2021-08-16	Cutaneous T-Cell Lymphoma	PANOBINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01578499	A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)	Phase 3	131	2018-03-16	Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT04101331	Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides	Phase 2	108	2023-06-05	Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides	ACIMTAMIG	Its record names the disease	ClinicalTrials.gov
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2	77	2022-05-04	Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma	TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00896493	Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma	Phase 2	38	2023-05-11	Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Cutaneous T-cell Lymphoma	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT03713320	SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides	Phase 2	37	2022-04-08	Cutaneous T-Cell Lymphoma/Mycosis Fungoides	COBOMARSEN, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01396070	Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level	Phase 2	36	2017-04-05	Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 89

See all 89 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PG -Mechlorethamine-MCH (Nitrogen Mustard) 0.02% PG Gel vs AP- Mechlorethamine-MCH (NM) 0.02% Compounded in Aquaphor: serious adverse events	0 of 128	0 of 127	255	NCT00168064	Trial comparisons
Bexarotene Exposed vs Bexarotene Naive: deaths from any cause	3 of 79	3 of 60	139	NCT00425555	Trial comparisons
Bexarotene Exposed vs Bexarotene Naive: serious adverse events	33 of 79	23 of 60	139	NCT00425555	Trial comparisons
Brentuximab Vedotin vs Methotrexate or Bexarotene: deaths from any cause	22 of 66	25 of 62	128	NCT01578499	Trial comparisons
Brentuximab Vedotin vs Methotrexate or Bexarotene: serious adverse events	18 of 66	18 of 62	128	NCT01578499	Trial comparisons
TSEBT Only vs TSEBT & Vorinostat: serious adverse events	1 of 14	0 of 14	28	NCT01187446	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Overall Response Rate (ORR)	6 of 16	0 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Incidence of Adverse Events	15 of 16	12 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): deaths from any cause	4 of 16	6 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): serious adverse events	4 of 16	5 of 12	28	NCT03063632	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials42

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32941647	RESULT	1	PubMed
25795722	RESULT	1	PubMed
22981498	RESULT	1	PubMed
19951879	RESULT	1	PubMed
19789316	RESULT	1	PubMed
12543862	RESULT	1	PubMed
41920467	DERIVED	1	PubMed
41651641	DERIVED	1	PubMed
40601335	DERIVED	1	PubMed
40546724	DERIVED	1	PubMed

1 to 10 of 42

See all 42 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009691

GET https://conductscience.org/api/diseases/v1/MONDO_0009691/drugs?page=2

API reference For AI assistants